A prospective study of fifty patients found that several 7T MRSI metabolite ratios distinguished glioblastoma, IDH-mutant ...

Children diagnosed with diffuse midline gliomas often die within a year after their initial diagnosis since there are no effective treatments yet for this rare cancer. But researchers now have a ...

Cancer is a sneaky disease. Find one method of treating it successfully, and it finds another way to survive. Take, for example, pediatric diffuse midline gliomas, brain tumors that are among the most ...

Please provide your email address to receive an email when new articles are posted on . A patient’s frailty should be considered when determining fractionation for WHO grade 4 adult-type diffuse ...

Newswise — The treatment of adult diffuse glioma faces numerous challenges. Although detailed studies on its genomic alterations are underway, subtype-specific susceptibilities remain unclear, making ...

Newswise — ARLINGTON, Va., June 26, 2025 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) focuses on the use of radiation therapy to treat adult patients with World ...

Hypofractionated radiation therapy with concurrent and adjuvant temozolomide is conditionally recommended for elderly patients. HealthDay News — In a clinical practice guideline issued by the American ...

Modeyso is the first FDA-approved systemic therapy for H3 K27M-mutant diffuse midline glioma, targeting both adult and pediatric patients. Clinical trials demonstrated a 22% overall response rate with ...

Dordaviprone targets mitochondrial protease and dopamine receptor D2, representing a novel approach in cancer therapy for H3 K27M-mutant diffuse glioma. The drug application seeks accelerated FDA ...

Historical standards for H3 K27M–mutant diffuse midline glioma treatment may harm healthy central nervous system cells, according to Ashley L. Sumrall, MD. Sumrall, a neuro-oncologist at Atrium Health ...